(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide-13CD3; (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide-13CD3; 2-Bromo ?-Ergocryptine Mesylate-13CD3; (5’?)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Methanesulfonate-13CD3; 2-Bromoergocryptine-13CD3; Bagren-13CD3; Bromocriptine Methanesulfonate-13CD3; Bromocryptine Mesylate-13CD3; CB 154-13CD3; Parlodel-13CD3; Pravidel
Bromocriptine-13C-d3 is a fully characterized chemical compound used as a reference standard of API Bromocriptine. The standard offered is compliant with regulatory guidelines. Bromocriptine-13C-d3 is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - 25614-03-3 (non-labelled)
